| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
5-HT1 Receptor
NAN-190 hydrobromide targets the serotonin 5-HT1A receptor, where it acts as an antagonist. By blocking 5-HT1A receptor signaling, it modulates neurotransmission. This receptor is a key regulator of serotonergic activity and is involved in mood, anxiety, and stress responses. Its antagonism by NAN-190 makes it a useful tool for studying the role of 5-HT1A receptors in various physiological and pathological processes. |
|---|---|
| ln Vitro |
In vitro, NAN-190 hydrobromide acts as a 5-HT1A receptor antagonist. Its activity is typically assessed by measuring its ability to inhibit agonist-induced responses in cells or tissues expressing 5-HT1A receptors. Standard in vitro assays include receptor binding studies using radiolabeled ligands such as [3H]-8-OH-DPAT and functional assays measuring cAMP accumulation or [35S]GTPγS binding.
|
| ln Vivo |
The effective dose of fluoxetine is injected concurrently with NAN-190 hydrobromide (0.5 mg/kg, ip). In 6-OHDA lesioned rats, NAN-190 reverses the fluoxetine's catalepsy-improving effect[2].
In vivo, NAN-190 hydrobromide is used as a research tool to study the role of 5-HT1A receptors in behavior and physiology. It has been shown to reverse the catalepsy-improving effect of fluoxetine in 6-OHDA lesioned rats. By blocking 5-HT1A receptors, it modulates serotonergic neurotransmission and can be used to study the effects of 5-HT1A receptor blockade on mood, anxiety, and motor function. |
| Enzyme Assay |
For non-cell-based receptor binding assays, NAN-190 hydrobromide can be evaluated using membrane preparations from cells expressing human 5-HT1A receptors. Radioligand binding displacement experiments are performed using a suitable radiolabeled ligand such as [3H]-8-OH-DPAT. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-90 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled 8-OH-DPAT. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing human 5-HT1A receptors are cultured in appropriate media. For functional assays, the inhibition of forskolin-stimulated cAMP accumulation is measured. Cells are treated with various concentrations of NAN-190 hydrobromide in the presence of a 5-HT1A receptor agonist. cAMP levels are measured using ELISA or HTRF-based detection. The compound's ability to reverse the agonist-induced inhibition of cAMP accumulation is assessed, and IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
For in vivo animal studies, NAN-190 hydrobromide can be administered to rodents via intraperitoneal injection. In models of Parkinson's disease, its effects on motor function and catalepsy are assessed. In models of anxiety or depression, behavioral tests are performed. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
NAN-190 hydrobromide has a molecular weight of 474.39 and a molecular formula of C23H28BrN3O3. It is supplied with a purity of ≥98%. The compound should be stored at -20°C for long-term stability. It is soluble in DMSO and can be formulated for both in vitro and in vivo administration. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of NAN-190 hydrobromide has not been extensively reported. As a 5-HT1A receptor antagonist, potential adverse effects may include modulation of serotonergic signaling. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies.
|
| References |
|
| Additional Infomation |
NAN 190 hydrobromide is a hydrobromide produced by reacting NAN 190 with an equivalent amount of hydrobromic acid. It is a serotonergic antagonist. It contains NAN 190(1+).
See also: Nan 190 (note moved to). NAN-190 hydrobromide (CAS 115338-32-4) is a 5-HT1A receptor antagonist. It is widely used in neuropharmacology to study receptor specificity, neurotransmitter feedback mechanisms, and behavioral responses. It is a valuable tool for understanding serotonin-dependent physiological and psychological processes. It is available for research purposes only. |
| Molecular Formula |
C23H28BRN3O3
|
|---|---|
| Molecular Weight |
474.39
|
| Exact Mass |
473.131
|
| CAS # |
115338-32-4
|
| Related CAS # |
NAN-190;102392-05-2
|
| PubChem CID |
107966
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
560.8ºC at 760mmHg
|
| Flash Point |
293ºC
|
| Vapour Pressure |
1.32E-12mmHg at 25°C
|
| LogP |
3.792
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
552
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)C4=CC=CC=C4C3=O.Br
|
| InChi Key |
AXRUEPFPTQYHQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H27N3O3.BrH/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28;/h2-5,8-11H,6-7,12-17H2,1H3;1H
|
| Chemical Name |
2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]isoindole-1,3-dione;hydrobromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 16.67 mg/mL (35.14 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1080 mL | 10.5399 mL | 21.0797 mL | |
| 5 mM | 0.4216 mL | 2.1080 mL | 4.2159 mL | |
| 10 mM | 0.2108 mL | 1.0540 mL | 2.1080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
